Clinical trials: Hepatic Steatosis
Hepatic Encephalopathy, Cirrhosis
Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome
Investigating the impact of hepatic encephalopathy on default mode networks within the brain to provide more clues with understanding the physiology of consciousness and predicting the reversibility of comatose states.
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
- Trial name
- NCT02083367
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OSF Healthcare System
Osteoporosis, Obesity
China Health Big Data
In this nationwide multi center study the investigators combine the low dose chest CT scan data with QCT technology, to measure the BMD of spine, VAT and liver fat in the health check subjects.
- Conditions
- Osteoporosis, Obesity, Liver Steatoses
- Trial name
- China biobank (NCT03699228)
- Where
- 6 sites in China
- Volunteers
- 30,000 people
- Sponsor
- Beijing Jishuitan Hospital
Pancreatic Steatosis, Metabolic Syndrome X
Study for the Identification of a Score to Assess Intrapancreatic Fat Through Eco-Elastography and Its Correlation With Metabolic Syndrome and Insulin-Secreting Cells.
Brief Summary of the SPES Clinical Study The SPES clinical study aims to evaluate the relationship between pancreatic fat accumulation (pancreatic steatosis) and metabolic health.
- Conditions
- Pancreatic Steatosis, Metabolic Syndrome X, Diabetes Mellitus
- Trial name
- SPES (NCT06801769)
- Testing
- C-peptide
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Catholic University of the Sacred Heart
Non-alcoholic Fatty Liver Disease
Fructose and Liver Diseases in Youth: Help Them FLY
Obesity has been increasing all over the world. This has lead to a significant increase of a liver disease in children called non-alcoholic fatty liver disease (NAFLD).
- Trial name
- FLY (NCT05528471)
- Testing
- Dietary intervention
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University of Alberta
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections
Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIV
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is an increasingly recognized comorbidity in people living with human immunodeficiency virus (HIV).
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections, Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis
- Trial name
- NCT07861594
- Volunteers
- 250 people
- Sponsor
- Assiut University
Liver Stiffness
Multi-parametric Magnetic Resonance Imaging for the Precise Diagnosis and Quantitative Study of Liver Steatosis, Inflammation, and Fibrosis in Chronic Liver Disease.
To construct a novel, non-invasive, accurate, and convenient method to achieve the degree of liver damage is an important general problem in the management of patients with chronic liver disease.
- Trial name
- NCT06463366
- Testing
- 3D-MRE,MRI-PDFF
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shengjing Hospital
Steatosis of Liver
Liver Fat and Glucagon Resistance
One in four adults worldwide have too much fat stored in the liver which is known as metabolic associated steatotic liver disease (MASLD). This was previously known as non- alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT06154096
- Testing
- Acute glucagon infusion
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Metabolic Dysfunction-Associated Fatty Liver Disease, Obesity, Adolescent
Effect of L-citrulline and HIIT on Arterial Stiffness, Body Composition, and Lipid Profile in Adolescents with Steatosis Associated with Metabolic Dysfunction (MASLD)
Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) accelerate the appearance of arterial stiffness due to inflammatory and oxidative stress mechanisms producing increased vascular tone and increasing the…
- Conditions
- Metabolic Dysfunction-Associated Fatty Liver Disease, Obesity, Adolescent, Arterial Stiffness
- Trial name
- NCT05778266
- Testing
- L-citrulline, Carboxymethyl cellulose, High Intensity Intervals Training
- Where
- Mexico
- Volunteers
- 43 people
- Sponsor
- Universidad de Guanajuato
Moderate Liver Impairment, Severe Liver Impairment
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
The purpose of this study is to investigate the effect of impaired liver function on the drug levels, safety, and tolerability of BMS-986036 in participants with moderate and severe liver impairment.
- Trial name
- NCT04634149
- Testing
- BMS-986036
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Non-Alcoholic Fatty Liver Disease, Liver Steatosis
Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)
The goal of this clinical study is to compare the therapeutic effect of Dulaglutide and Empagliflozin in patients with Diabetes Mellitus type 2 and Non-Alcoholic Fatty Liver Disease.
- Trial name
- NAMELS-18 (NCT05946148)
- Testing
- Empagliflozin, Dulaglutide, Control Rx
- Where
- Greece
- Volunteers
- 78 people
- Sponsor
- National and Kapodistrian University of Athens
Nonalcoholic Fatty Liver Disease
Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease
To study the effects of a low free sugar diet on lipid profile, glycemic indices, liver enzymes, inflammatory factors and hepatic steatosis and fibrosis in patients with Nonalcoholic fatty liver disease, 50 patients who referred…
- Trial name
- NCT04369521
- Testing
- low free sugar diet
- Where
- 2 sites in Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes
Sphingolipids are associated with metabolic diseases. Distribution of plasma sphingolipids in type 1 and type 2 diabetes has never been studied.
- Trial name
- CERADIAB (NCT03447964)
- Testing
- dosing of sphingolipids
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Hepatic Steatosis, Dietary Fructose Exposure
Dietary Fructose on Microbiota and Hepatosteatosis
The consumption of sugar-sweetened beverages (SSB) has increased steadily over the past decades, resulting in the dramatic increase of fructose intake as it is one of the main ingredients of artificial sweeteners.
- Trial name
- NCT04898621
- Testing
- 75g fructose solution, 150g fructose solution
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Liver Fibrosis, Liver Steatosis
The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis
Evaluate the feasibility of the Liver Incyte system for liver elasticity measurement in healthy volunteers and patients with liver fibrosis.
- Trial name
- NCT03957070
- Testing
- Liver Incyte
- Where
- 2 sites in United States, Canada
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sonic Incytes
Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.
- Trial name
- NCT03884075
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Alcoholic Fatty Liver Disease
Effect of Indo-Mediterranean Diet on Hepatic Steatosis and Fibrosis in NAFLD Children
NAFLD encompasses the entire spectrum of Fatty liver disease in individuals without significant alcohol consumption, ranging from fatty liver to steatohepatitis to cirrhosis.
- Trial name
- NCT05073588
- Testing
- Indo Mediterranean diet, Calorie restricted diet
- Where
- India
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Institute of Liver and Biliary Sciences, India
Steatosis of Liver
Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.
The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical…
- Trial name
- MASLD (NCT07652892)
- Where
- 2 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASH With Fibrosis
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
MASLD (Metabolic dysfunction-associated steatotic liver disease) is a condition where fat builds up in the liver. It is the most common cause of liver disease worldwide.
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASH With Fibrosis, Steatosis of Liver
- Trial name
- FLOURISH (NCT07013916)
- Testing
- fructose, glucose
- Where
- 2 sites in United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Non-Alcoholic Fatty Liver Disease
Effect of Dapagliflozin on Metabolic Parameters in Patients With Non-Alcoholic Fatty Liver Disease
This study was designed to assess the effect of dapagliflozin on body weight, blood sugar, liver enzymes, and blood fats in adults with non-alcoholic fatty liver disease (NAFLD), a condition involving excess fat accumulation in…
- Trial name
- NCT07881796
- Testing
- Dapagliflozin (10mg Tab)
- Where
- Pakistan
- Volunteers
- 146 people
- Sponsor
- Shalamar Hospital
Visceral Obesity, Non-alcoholic Fatty Liver
Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity
This study aims to evaluate the effect of daily intake of a specific combination of different natural histidine-related amino acids in combination with dietary recommendations, in the reduction of visceral fat, as well as their…
- Conditions
- Visceral Obesity, Non-alcoholic Fatty Liver, Postmenopausal
- Trial name
- FATHIS+ (NCT06377631)
- Testing
- Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine
- Where
- 2 sites in Spain
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fundació Eurecat